Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Perspective Therapeutics (CATX) over the last 16 years, with Q3 2025 value amounting to -$0.35.

  • Perspective Therapeutics' EPS (Basic) fell 6666.67% to -$0.35 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.51, marking a year-over-year increase of 258.06%. This contributed to the annual value of -$0.01 for FY2024, which is 9915.34% up from last year.
  • According to the latest figures from Q3 2025, Perspective Therapeutics' EPS (Basic) is -$0.35, which was down 6666.67% from -$0.3 recorded in Q2 2025.
  • In the past 5 years, Perspective Therapeutics' EPS (Basic) registered a high of $0.01 during Q1 2023, and its lowest value of -$0.91 during Q4 2023.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.18 (2024), whereas its average is -$0.21.
  • Data for Perspective Therapeutics' EPS (Basic) shows a peak YoY increase of 20000.0% (in 2023) and a maximum YoY decrease of 263314.73% (in 2023) over the last 5 years.
  • Quarter analysis of 5 years shows Perspective Therapeutics' EPS (Basic) stood at -$0.01 in 2021, then plummeted by 400.0% to -$0.05 in 2022, then tumbled by 1720.0% to -$0.91 in 2023, then soared by 32.97% to -$0.61 in 2024, then skyrocketed by 42.62% to -$0.35 in 2025.
  • Its EPS (Basic) was -$0.35 in Q3 2025, compared to -$0.3 in Q2 2025 and -$0.25 in Q1 2025.